IDXG: the cash flow

MyFinsight

For the quarter ending 2026-03-31, IDXG had $142K increase in cash & cash equivalents over the period. $142K in free cash flow.

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net income	721	22,657	911	1,007
Depreciation and amortization	118	118	111	196
Asset impairment - lab supplies	-	0	0	198
Amortization of deferred financing fees	-	16	16	26
Stock-based compensation	4	4	7	24
Deferred taxes	277	-21,254	-	-
Credit loss expense	-	-	-	0
Change in fair value of note payable	-	-23	-105	18
Amortization on operating lease right of use asset	107	103	100	193
Accounts receivable	276	-317	-1,265	-1,313
Other current assets	-355	21	-14	227
Other long-term assets	-	1	-	-
Interest accretion expense	-	-	-	0
Accounts payable	-47	-390	-8	-409
Accrued salaries and bonus	-1,172	456	-601	-176
Accrued liabilities	-	-273	-	-
Other accrued expenses	601	-	16	-401
Operating lease liabilities	-130	-99	-98	-185
Bad debt expense reversal	-	-	-	0
Long-term liabilities	110	95	100	214
Net cash provided by operating activities	283	2,138	1,938	1,755
Purchase of property and equipment	141	38	117	201
Net cash used in investing activities	-141	-38	-117	-201
Payments made on note payable	-	1,000	900	2,500
Series c conversion costs	-	0	0	13
Cash paid for repurchase of restricted shares	-	18	-	-
Net cash used in financing activities	-	-1,018	-900	-2,513
Net increase (decrease) in cash and cash equivalents	142	1,082	921	-959
Cash and cash equivalents beginning	2,505	38	1,461	-
Cash and cash equivalents ending	2,647	1,082	1,423	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.